Logo.png
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
13 sept. 2023 08h30 HE | Imunon, Inc.
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...
Logo.png
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
07 sept. 2023 16h30 HE | Imunon, Inc.
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) --...
Logo.png
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 09h05 HE | GRI Bio, Inc.
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Logo.png
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
05 sept. 2023 08h30 HE | Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th...
Logo.png
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
24 août 2023 16h05 HE | Imunon, Inc.
CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Logo.png
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
07 août 2023 08h35 HE | GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
Logo.png
GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference
03 août 2023 08h30 HE | GRI Bio, Inc.
- Live moderated webcast fireside chat today, August 3rd at 11:15 AM ET LA JOLLA, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology...
Logo.png
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
24 juil. 2023 09h00 HE | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
Logo.png
GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series
05 juil. 2023 08h45 HE | GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
Logo.png
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
27 juin 2023 08h45 HE | GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...